x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

pharmaphorum Podcast

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for

science life sciences

All Episodes

19:18

Compliance baked into the design core: On AI in life...

pharmaphorum Podcast ·

2025/08/07

When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems. The conversation covers commercial model evolution, precision engagement, the importance of quality data in a

en-us

18:40

Putting patients and their families first: Dr Corina...

pharmaphorum Podcast ·

2025/08/05

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer.In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitment to innovation in the oncological field. Tune in to this and other ASCO 2025 conversations here. You can also listen to episode 196a of

en-us

28:19

Enhancing anti-tumour activity: A post-ASCO...

pharmaphorum Podcast ·

2025/07/31

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases. At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC. In a post-ASCO pharmaphorum podcast, Dan Schmitt, CEO of Actuate,

en-us

19:05

Redefining the Future of Melanoma Treatment:...

pharmaphorum Podcast ·

2025/07/29

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how the company develops novel immunotherapy products for the treatment of multiple cancers, as well as its

en-us

30:40

Why Datavant bought Aetion, and what comes next, with...

pharmaphorum Podcast ·

2025/07/24

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that the acquisition has closed, the pharmaphorum podcast welcomes Arnaub Chatterjee, president and general manager of life sciences at Datavant, to discuss what that integration will look like -- and what the implications are for the pharma industry.Chatterjee discusses how the acquisition came about and what the strategic fit looks like between the two

en-us

21:24

Post-ASCO 25: Pamela Tenaerts on CGTs and...

pharmaphorum Podcast ·

2025/07/22

When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given the 15 years that patients must still engage with the trial after receiving the medication.In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle long-term follow-up care for cell and gene therapy cancer

en-us

25:02

Immune mediation, B-cell depletion, and female...

pharmaphorum Podcast ·

2025/07/17

In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, and Brennan talks about the potential of B-cell depletion therapies, as well as the challenges and opportunities in developing novel biotechnology. Brennan also speaks to being a female leader in this field. You can also listen to episode 191a of the pharmaphorum podcast in the

en-us

15:26

Ben Sidders on integrating causality in AI for R&D...

pharmaphorum Podcast ·

2025/07/15

For AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essential for technical and regulatory success in drug discovery.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ben Sidders, chief scientific officer at Biorelate, a company leveraging advanced data science methods to transform the focus and impact of drug discovery and development. Sidders discusses how integrating causality in AI for

en-us

25:32

On nuclear medicine and oncology, SHINE technologies

pharmaphorum Podcast ·

2025/07/10

Radiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, such as in oncology.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a nuclear fusion company mastering more immediate applications of fusion – such as in producing cancer-fighting medicine. Piefer provides an overview of the nuclear medicine field and discusses clinical research

en-us

01:04:16

Unicorns, AI, and the future of health: Highlights...

pharmaphorum Podcast ·

2025/07/08

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands today – and where it’s headed next.Amid economic uncertainty and shifting regulatory priorities, pharma, health tech, and care delivery are all racing to prove value and scale innovation. In this special extended episode of the pharmaphorum podcast, Deep Dive editor Eloise McLennan sat down with

en-us

16:33

On patient-centric treatment decisions and the value...

pharmaphorum Podcast ·

2025/07/03

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decision.In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, about his recent work as one of the editors of – and a chapter contributor to – the first edition of "𝘏𝘢𝘯𝘥𝘣𝘰𝘰𝘬 𝘰𝘧 𝘎𝘦𝘯𝘦𝘳𝘢𝘭𝘪𝘻𝘦𝘥 𝘗𝘢𝘪𝘳𝘸𝘪𝘴𝘦 𝘊𝘰𝘮𝘱𝘢𝘳𝘪𝘴𝘰𝘯𝘴: 𝘔𝘦𝘵𝘩𝘰𝘥𝘴

en-us

13:40

Maximising value by uniting the digital backbone: On...

pharmaphorum Podcast ·

2025/07/01

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development. In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partnership, Novo aiming to accelerate clinical trials and launches by uniting business and IT on the Veeva Development Cloud to enhance collaboration,

en-us

18:11

The changing landscape of drug clinical assessment:...

pharmaphorum Podcast ·

2025/06/24

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access and healthcare consulting at Cencora, about the JCA, as yet unanswered

en-us

19:22

Precision, speed, impact: Evolving mass spectrometry...

pharmaphorum Podcast ·

2025/06/19

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science.In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that deeply, accurately, and efficiently characterise complex molecules. Sherman discusses the practical impact of this new technology for R&D, MOBILion's

en-us

14:14

IMUNON at ASCO 2025: Changing the micro-tumour...

pharmaphorum Podcast ·

2025/06/17

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today.Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in advanced ovarian

en-us

18:37

Treating primary bone cancer: The potential of...

pharmaphorum Podcast ·

2025/06/13

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid

en-us

09:25

Servier’s ASCO 2025 Data: Advancing IDH-Mutated...

pharmaphorum Podcast ·

2025/06/05

At ASCO 2025, Servier presented data in the IDH-mutated cancer space.Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company’s Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress this year. Listen to this and other interviews from ASCO 2025 here.

en-us

38:15

Where innovation meets collaboration: Live from...

pharmaphorum Podcast ·

2025/06/05

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organisations into close, purposeful proximity, providing a structural

en-us

09:57

Live from ASCO 2025: Boehringer Ingelheim on unmet...

pharmaphorum Podcast ·

2025/06/04

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers.In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the specifics of the company’s data presentations. The conversation also touches upon highlights from this

en-us

19:07

Bringing patients to research centres: Using AI to...

pharmaphorum Podcast ·

2025/05/31

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI.Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants. With growing industry pressure for greater trial access, a more focused effort to bring

en-us

324 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter